Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia.
Liping WangGuang LinZhongyuan ZuoYarong LiSeul Kee ByeonAkhilesh PandeyHugo J BellenPublished in: Science advances (2022)
Recessive variants in GBA1 cause Gaucher disease, a prevalent form of lysosome storage disease. GBA1 encodes a lysosomal enzyme that hydrolyzes glucosylceramide (GlcCer) into glucose and ceramide. Its loss causes lysosomal dysfunction and increased levels of GlcCer. We generated a null allele of the Drosophila ortholog Gba1b by inserting the Gal4 using CRISPR-Cas9. Here, we show that Gba1b is expressed in glia but not in neurons. Glial-specific knockdown recapitulates the defects found in Gba1b mutants, and these can be rescued by glial expression of human GBA1 . We show that GlcCer is synthesized upon neuronal activity, and it is transported from neurons to glia through exosomes. Furthermore, we found that glial TGF-β/BMP induces the transfer of GlcCer from neurons to glia and that the White protein, an ABCG transporter, promotes GlcCer trafficking to glial lysosomes for degradation.
Keyphrases
- neuropathic pain
- mesenchymal stem cells
- spinal cord
- crispr cas
- stem cells
- endothelial cells
- poor prognosis
- oxidative stress
- type diabetes
- bone marrow
- copy number
- dna methylation
- metabolic syndrome
- intellectual disability
- transforming growth factor
- blood glucose
- autism spectrum disorder
- replacement therapy
- insulin resistance
- genome wide
- fluorescent probe
- pluripotent stem cells